Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7326/0003-4819-138-3-200302040-00028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Wernicke encephalopathy in a patient with drug-induced liver failure: a case report.
Front Nutr
January 2025
Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Introduction: Wernicke encephalopathy is a metabolic disease mainly associated with vitamin B1 deficiency, which is common in chronic alcoholism. Non-alcoholic Wernicke encephalopathy is difficult for early diagnosis.
Case Presentation: One case involved a 62-year-old man who was admitted to hospital with drug-induced liver failure.
SWEET'S SYNDROME ASSOCIATED WITH PHEOCHROMOCYTOMA: A RARE CASE REPORT AND REVIEW OF LITERATURE.
Acta Endocrinol (Buchar)
January 2025
Municipal Clinical Hospital - Urology, Cluj-Napoca.
Background: Sweet's syndrome (SS) or acute febrile neutrophilic dermatosis is a dermatological illness that can be described by tender erythematous plaques or nodules and acute onset fever. The etiology is multifactorial and is not fully understood. SS is separated in three subclasses: classical, malignancy-associated, and drug-induced.
View Article and Find Full Text PDFAntituberculosis Therapy-Induced Acute Liver Failure in a Renal Transplant Recipient: A Case Report.
Cureus
December 2024
Nephrology, University Clinical Center of Serbia, Belgrade, SRB.
To prevent organ rejection, renal transplant (RT) recipients must take immunosuppressive medicines, which make them more susceptible to infections such as tuberculosis (TB). Hepatotoxicity, which can vary from asymptomatic increased liver enzymes to severe liver failure, is the most prevalent side effect of first-line antituberculosis (AT) drugs. Treating TB in RT patients involves unique concerns since AT medications might interact with immunosuppressive medications, potentially reducing efficacy or increasing toxicity.
View Article and Find Full Text PDFIncreased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity.
BMC Immunol
January 2025
Department of Oncology and Hematology, Oulu University Hospital, Oulu, Finland.
Vanishing bile duct syndrome (VBDS) is a serious drug induced liver injury characterized by chronic cholestasis and loss of intrahepatic bile ducts. VBDS has been reported also following checkpoint inhibitor treatment. We compared CD3 + , CD4 + , CD8 + , CD20 + , CD57 + , PD-1 + and PD-L1 + lymphocyte infiltrates in liver biopsies of patients that encountered VBDS (n = 2) or hepatotoxicity (n = 3) after pembrolizumab (n = 4) or nivolumab (n = 1) treatment with samples from normal liver (n = 10), non-alcohol steatohepatitis (NASH, n = 10), primary biliary cholangitis (PBC, n = 10) or pembrolizumab-treated patients without adverse events (n = 2).
View Article and Find Full Text PDFHepatobiliary Adverse Events Associated With the KRAS p.G12C Inhibitor Sotorasib.
Pharmacoepidemiol Drug Saf
February 2025
Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Purpose: The p.G12C mutation in KRAS is commonly found in many cancers and was previously untreatable until drugs like sotorasib were developed. However, up to 15% of patients treated with sotorasib have experienced hepatobiliary adverse events.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!